platinum has been researched along with indazoles in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| Authors | Studies |
|---|---|
| Abramski, JK; Hartinger, CG; Jarosz, M; Keppler, BK; Polec-Pawlak, K; Semenova, O; Timerbaev, AR | 1 |
| Hartinger, CG; Keppler, BK | 1 |
| Bischofs, E; Eichbaum, M; Eickhoff, R; Fehm, T; Fersis, N; Fricke, HC; Gebauer, G; Lenz, F; Mayer, C; Schmidt, M; Schneeweiss, A; Sohn, C; Solomayer, E; Wallwiener, M | 1 |
| Arcangeli, V; Brandes, AA; Cecere, SC; Cinieri, S; Daniele, G; Di Maio, M; Di Napoli, M; Gallo, C; Lorusso, D; Maltese, G; Mosconi, AM; Orditura, M; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Ricci, C; Salutari, V; Sambataro, D; Scambia, G; Tamberi, S | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ | 1 |
| Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L | 1 |
| Konstantinopoulos, PA; Matulonis, UA | 1 |
| Wu, L; Zhong, L | 1 |
| Schorge, JO | 1 |
| Long, X; Zhou, Q; Zou, D | 1 |
| Bajpai, J; Deodhar, K; Ghosh, J; Gulia, S; Gupta, S; Maheshwari, A; Rath, S; Shylasree, TS; Thakur, M | 1 |
| Alvarez, N; Colombo, N; dePont Christensen, R; Gonzalez Martin, A; Heitz, F; Marqués, C; Meirovitz, M; Sanchez Lorenzo, L; Sanchez, J; Selle, F; van Gorp, T | 1 |
| Liu, M; Liu, T; Sun, L; Tan, S; Tang, J; Xiao, W; Zhou, X | 1 |
| Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J | 1 |
| Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M | 1 |
| Belotte, J; Clements, A; Fleming, EL; Gray, HJ; Gupta, D; Hamilton, E; Hardesty, MM; Keeton, EK; Konecny, GE; Krivak, TC; Moore, RG; Richardson, DL; Wang, P; Wright, GS | 1 |
| Domchek, SM; Donze, A; Gosselin, MK; Karasic, T; Massa, R; Mick, R; O'Hara, M; Onyiah, C; Reiss, KA; Schneider, C; Teitelbaum, U; Tondon, R; Vonderheide, RH | 1 |
1 review(s) available for platinum and indazoles
| Article | Year |
|---|---|
CE in anticancer metallodrug research--an update.
Topics: Antineoplastic Agents; Cisplatin; Electrophoresis, Capillary; Humans; Indazoles; Molecular Structure; Platinum; Protein Binding; Ruthenium Compounds; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Atomic; Stereoisomerism | 2007 |
7 trial(s) available for platinum and indazoles
| Article | Year |
|---|---|
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Pyrimidines; Sulfonamides | 2011 |
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrimidines; Sulfonamides; Treatment Outcome | 2015 |
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Peritoneal Neoplasms; Piperidines; Platinum; Progression-Free Survival; Time Factors | 2021 |
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea | 2022 |
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines; Platinum | 2022 |
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hypertension; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Nivolumab; Pancreatic Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
9 other study(ies) available for platinum and indazoles
| Article | Year |
|---|---|
Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Topics: Antineoplastic Agents; Binding, Competitive; Blood Proteins; Electrophoresis, Capillary; Humans; In Vitro Techniques; Indazoles; Kinetics; Mass Spectrometry; Organometallic Compounds; Platinum; Protein Binding; Ruthenium Compounds; Serum Albumin; Transferrin | 2006 |
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment | 2018 |
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States | 2019 |
Chemotherapy-free, but not quite free chemotherapy.
Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum | 2019 |
Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer.
Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum | 2019 |
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Pyrimidines; Retrospective Studies; Sulfonamides | 2020 |
Chronic stress induces platinum and Niraparib resistance in mouse models of ovarian cancer.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Models, Biological; Ovarian Neoplasms; Piperidines; Platinum; Stress, Psychological | 2022 |
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |